CTLA4 and metastatic melanoma: The anti-CTLA-4 monoclonal antibody ipilimumab (fully human IgG1, Bristol-Myers Squibb) increased the median overall survival (OS) among metastatic melanoma patients in a pooled analysis of phase II and III data and some patients even survived 10 years after treatment (8).